CD38 and acute myeloid leukemia: Using LSC-like cell lines, as well as CD34+CD38− primary AML cells and bone marrow (BM) cells from healthy donors, we demonstrated that the combination of venetoclax and ATO synergistically and selectively exhibits anti-AML activity in vitro, simultaneously sparing normal HSCs.